UDC.616.441-006.6- 036.82 - 037 DOI: 10.15587/2519-4798.2019.174444

SURVIVAL OF PATIENTS WITH THYROID PAPILLARY AND FOLLICULAR CARCINOMA: SIMILARITY AND DIFFERENCE OF PROGNOSTIC FACTORS (cohort retrospective study)

B. Guda

При аналізі причин, які мають бути важливими для прогнозування захворювання та впливу на виживання пацієнта зі злоякісними пухлинами щитоподібної залози, дослідники вивчають багато факторів. **Метою дослідження** було визначити показники кумулятивного виживання пацієнтів з диференційованими карциномами щитоподібної залози різного гістологічного типу залежно від біологічних характеристик пухлин і деяких клінічних чинників.

Матеріали і методи: Ретроспективне дослідження когорти хворих, які з приводу злоякісної пухлини перенесли операцію на щитоподібній залозі. Проаналізована інформація щодо пацієнтів (вік і стать, гістологічний тип, розмір і категорії карцином (TNM), їх інвазійні властивості, наявність мультифокальності), а також щодо клінічних характеристик захворювання (стадія, обсяг оперативного втручання та радіойодного лікування, групи ризику виникнення рецидиву, кількість балів за системою MACIS).

Результати: Для хворих з папілярними чи фолікулярними карциномами чинники, які проаналізовані є важливими щодо подальшого прогнозу. Найсуттєвішим є розмір пухлини, з яким пов'язані інші – метастазування, мультифокальний ріст, інтра- та екстратиреоїдна інвазія, виникнення рецидиву. У пацієнтів до 45 років з карциномою без екстратиреоїдного її розповсюдження і метастазування, яким проведена тиреоїдектомія, сприятливий прогноз хвороби не залежить від типу пухлини. За інших умов вплив гістологічного типу карциноми (фолікулярна порівняно з папілярною) є важливішим, а у деяких випадках – для чоловіків, осіб у віці понад 60 років, за пухлини понад 40 мм, мультифокальних, з інтра- і, особливо, з екстратиреоїдною інвазією, за віддаленого метастазування, при проведенні тиреоїдектомії з дисекцією лімфовузлів, наявністю рецидивів – суттєво важливим.

Висновки. Результати досліджень підтверджують висновок, що найважливішим предиктороми персистенції/рецидиву захворювання чи смертності пацієнтів є гістологічний підтип диференційованих карцином щитоподібної залози, розмір пухлини, вік та стать

Ключові слова: naniлярна і фолікулярна карциноми, прогностичні чинники, MACIS

Copyright © 2019, B. Guda.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0).

1. Introduction

The current strategy of thyroid neoplasm management is based on principles including avoidance of excessive surgical intervention, decreased radioisotopes use, and less intensive follow-up in cases of patient from low and middle risk groups. More aggressive treatment tactics should be applied to patients with more aggressive tumors. It is emphasized that we need now new perspective data, in particular, data about prognostic factors giving a possibility to realize this task.

While studying the role of prognostic factors in patient survival, the majority of authors consider these factors in total for a group of differentiated thyroid carcinoma [1, 2]. Simultaneously, there is information on the existence of differences concerning clinical-pathological properties between different thyroid carcinoma – papillary (PTC) and follicular ones (FTC) including also prognostic factors [3, 4]. Moreover, the FTC diagnosis by itself is thought to be an independent negative prognostic factors factors have to be evaluated, compared, and confirmed separately for this carcinoma [6]. However, such investigations are rare.

2. The aim of the study

Retrospective determination of the survival rate of patients with thyroid differentiated carcinomas of different histological type, depending on the biological characteristics of the tumors and some clinical factors.

3. Materials and methods

A retrospective study has been carried out on the cohort of patients, which were operated because of differentiated thyroid cancers in 1994-2014. The studies were conducted in the clinic of the Institute of Endocrinology, in addition, data from the National Cancer Registry was used. The cohort includes 5,346 patients; among them there are 4,346 women and 1,000 men, their age being from 10 to 84 years (average age 40.9 ± 9.1 years); the PTC diagnosis was made for 4,818 patients, 528 persons were with the FTC diagnosis. The tumor classification was realized according to the 7th version of the TNM Classification.

The information of patients (age and sex, histological type, size and categories of carcinomas, their invasive properties, the presence of multifocal growth), as well as the clinical characteristics of the disease (stage, volume of surgical intervention and radioiodine treatment, risk of relapse group, number of points in the system MACIS) was analysed.

The statistical evaluation of obtained data was made using Pearson's criterion of distribution concordance $\chi^2(P_u)$. The survival curve was plotted according to the Kaplan-Meyer approach, a non-parametric log-rank test (P_1) was used to compare the index value of cumulative survival in groups. The critical significance level taken here is 0.05.

4. Results

The survival of cohort patients with FTC is lower comparing to the PTC patients survival (Fig. 1). For example, the FTC patients survival during 2, 5, 10, and 20 years reaches 98 %, 97 %, 94.8 %, and 94.3 %, respectively, the survival of PTC ones being 99.3 %, 99.0 %, 98.5 %, and 98.4 %, respectively (P=0.0001). The less favorable prognosis of FTC patients may be due to several factors. The analysis results of total patients groups with PTC and FTC show the prevalence of FTC patients with neoplasm above 20 mm as well as of patients with II, III, and IVa disease stages is higher comparing with the percent of PTC patients with the same parameters. The mortality among FTC patients is also higher. At the same time, the percent of the cohort patients with invasive PTC as well as the percent of multifocal tumors are also higher comparing to the FTC patients one (Table 1).




Fig. 1. Cumulative curves of patients' survival with papillary and follicular thyroid carcinoma

The prognosis for patients with thyroid cancer depends on sex of patients. The level of men survival is lower comparing to the level of women survival, especially for FTC patients (Table 2). Among male patients the percent of PTC and FTC above 20 mm, of tumors belonging to T3-T4 categories with intra-nodal metastases as well as the percent of PTC patients with the IV stage of disease are higher comparing to female patients (Table 3). The mortality level of males with the FTC exceeds this value for PTC by 5.5 times, the mortality of females with FTC being thrice higher comparing to PTC patients. Simultaneously, both among men and women higher FTC frequency with size above 20 mm is kept, the percent of patients with invasive and multifocal FTC being lower.

Table 1

	conort of alfroid caremonia patients. Requeiter of							
	patients with different type carcinoma, frequency of							
	patients with different disease stages, and mortality amo	ong						
patients with papillary and follicular carcinoma, n (%)								
	Carcinoma							

Cohort of thyroid carcinoma natients: frequency of

	Carcinoma					
Index	papillary (n=4818)	follicular (n=528)	P _x - value			
Tumors above 20 mm	1537 (31.9 %)	243 (46.0 %)	0.0000			
Tumors of the T3-T4b category	1294 (26.9 %)	145 (27.4 %)	0.7662			
Tumors of the N1a-N1ab category	1703 (35.3 %)	85 (16.1 %)	0.0000			
Tumors of M1 category	128 (2.7 %)	11 (2.1 %)	0.4318			
Intra-thyroid invasion	2848 (59.1 %)	220 (41.7 %)	0.0000			
Extra-thyroid invasion	1064 (22.1 %)	71 (13.4 %)	0.0000			
Multifocal growth	874 (18.1 %)	67 (12.7 %)	0.0017			
Disease stage: I	3801 (78.9 %)	374 (70.8 %)	0.0000			
II	339 (7.0 %)	53 (10.0 %)	0.0120			
III	339 (7.0 %)	60 (11.4 %)	0.0003			
IVa	314 (6.5 %)	33 (6.3 %)	0.8129			
IVb	12 (0.2 %)	1 (0.2 %)	0.7915			
IVc	13 (0.3 %)	7 (1.3 %)	0.0001			
Mortality	58 (1.2 %)	24 (4.5 %)	0.0000			

Table 2

Cumulative survival of different sex and	age patients wi	ith thyroid carcinomas	, (
--	-----------------	------------------------	-----

	Cumulative survival of different sex and age patients with thyroid carcinomas, %									
		Pap	illary carcin	oma			Foll	icular carcin	ioma	
Groups		survival te	erm, years	·	D value		survival te	erms, years		D. voluo
	2	5	10	20	$-P_{L}$ -value	2	5	10	20	$-P_{L}$ -value
	sex									
women	99.5	99.1	98.7	98.5	0.037	98.7	98.0	96.5	95.9	0.001
men	98.8	98.4	98.0	97.6	0.037	95.0	92.2	86.2	86.2	0.001
					age, years					
below 18	100	100	100	100		100	100	100	100	
19–40	99.9	99.7	99.7	99.7	0.000	99.2	99.2	99.2	99.2	0.000
41-60	99.6	99.0	98.7	98.7	0.000	99.3	97.6	95.0	95.0	0.000
above 60	96.0	94.2	90.1	87.1		92.0	90.8	85.9	-	

Table 4

Table 3 Cohort of thyroid carcinoma patients: frequency of Cohort of thyroid carcinoma patients: frequency of different sex patients with carcinoma of different patients with carcinoma of different properties, frequency properties, frequency of disease stages, and mortality of disease stages, and mortality among patients with among patients with papillary and follicular papillary and follicular carcinoma. n (%)

	(%)				
Index	Carcinoma				
muex	papillary	follicular	D voluo		
Women	n=3896	n=450	P_{χ} -value		
Tumors above 20 mm	1198 (30.7 %)	199 (44.2 %)	0.0000		
Category: T3-T4	995 (25.5 %)	117 (26.0 %)	0.8319		
Na1-N1ab	1271 (32.7 %)	65 (14.4 %)	0.0000		
M1	92 (2.4 %)	6 (1.3 %)	0.1642		
Intra-thyroid invasion	2269 (58.2 %)	192 (42.7 %)	0.0000		
Extra-thyroid invasion	819 (21.0 %)	63 (14.0 %)	0.0004		
Multifocal growth	718 (18.4 %)	58 (12.9 %)	0.0036		
Disease stage: I	3092 (79.4 %)	321 (71.3 %)	0.0000		
II	274 (7.0 %)	46 (10.2 %)	0.0141		
III	280 (7.2 %)	52 (11.6 %)	0.0009		
IV	250 (6.4 %)	31 (6.9 %)	0.7901		
Mortality	39 (1.0 %)	14 (3.1 %)	0.0001		
Men	n=922	n=78			
Tumors above 20 mm	339 (36.8 %)*	44 (56.4 %)*	0.0006		
Category:T3-T4	299 (32.4 %)*	34 (43.6 %)*	0.0446		
N1a-N1ab	432 (46.9 %)*	20 (25,6 %)*	0.0003		
M1	36 (3.9 %)*	5 (6.4 %)*	0.2838		
Intra-thyroid invasion	579 (62.8 %)*	38 (48.7 %)	0.0000		
Extra-thyroid invasion	245 (26.6 %)*	14 (17.9 %)	0.0000		
Multifocal growth	156 (16.6 %)	9 (11.5 %)	0.0009		
Disease stage: I	709 (76.9 %)	53 (67.9 %)	0.0747		
II	65 (7.0 %)	7 (9.0 %)	0.5277		
III	59 (6.4 %)	8 (10.3 %)	0.1907		
IV	89 (9.7 %)*	10 (12.8 %)	0.3684		
Mortality	19 (2.1 %)	10 (12.8 %)	0.0000		

Note: * - < 0.01 vs. the women

The survival level for PTC and FTC patients below 18 years reaches 100 %; it is the same for patients younger than 40, being somewhat lower for FTC patients of 41-60 years comparing to PTC ones (beginning from the 5 year term) and lower for persons above 60 (beginning from 2-year term) (Table 2). Simultaneously, the carcinoma analysis depending on the patients age suggests the higher percent of PTC cases with tumor size above 20 mm in persons below 18 comparing with elder patients; it concerns tumors of T3-T4 categories, metastazing tumors, patients with intra- or extra-thyroid invasion. In cases of FTC similar tendency is found only for frequencies of tumors above 20 mm and tumors of T3-T4 categories. At the same time, among FTC cases the percent of patients with intra- or extra-thyroid invasion, distant metastases, and multifocality is lower (Table 4).

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	papillary and	follicular carci	noma, n (%)				
papillary follicular P value Tumors above 20 mm 236 (47.2 %) 34 (77.3 %) 0.0001 Category: T3-T4 242 (48.4 %) 16 (36.4 %) 0.1253 N1a-N1ab 299 (59.8 %) 3 (68.%) 0.0000 M1 68 (13.6 %) 1 (2.3 %) 0.0304 Intra-thyroid invasion 397 (79.4 %) 15 (34.1 %) 0.0000 Extra-thyroid invasion 297 (79.4 %) 15 (34.1 %) 0.0000 Multifocal growth 93 (18.6 %) 1 (2.3 %) 0.0304 Intra-thyroid invasion 296 (33.1 %)* 80 (66.1 %) 0.0304 Patients of 19-40 years n=1991 n=121 0.0304 Tumors above 20 mm 659 (33.1 %)* 80 (66.1 %) 0.0000 Mal 432 (22.9 %)* 0 (0.0 %) 0.1024 Intra-thyroid invasion 1339 (67.3 %)* 57 (47.1 %) 0.0000 Multifocal growth 346 (17.4 %) 10 (8.8 %) 0.2142 Mortality 5 (0.3 %) 1 (0.8 %) 0.2142 Mortality 5 (0.3 %)	Index						
Patients below 18 n=500 n=44 value Tumors above 20 mm 236 (47.2 %) 34 (77.3 %) 0.0001 Category: T3-T4 242 (48.4 %) 16 (36.4 %) 0.1253 N1a-N1ab 299 (59.8 %) 3 (6.8 %) 0.0000 M1 68 (13.6 %) 1 (2.3 %) 0.0304 Intra-thyroid invasion 216 (43.2 %) 0 (0.0 %) 0.0000 Multifocal growth 93 (18.6 %) 1 (2.3 %) 0.0304 II 68 (13.6 %) 1 (2.3 %) 0.0304 Patients of n=1991 n=121 Tumors above 20 mm 659 (33.1 %)* 80 (66.1 %) 0.0000 M1 43 (2.2 %)* 0 (0.0 %) 0.1024 Intra-thyroid invasion 1339 (67.3 %)* 57 (47.1 %) 0.0000 M1 43 (2.2 %)* 0 (0.0 %) 0.5276 Patients of n=1846 n=273 Mortality 5 (0.3 %) 1 (0.8 %) 0.5276 Patients of n=1846 n=273 Tumors	Index	papillary	follicular	Ρ _γ -			
Category: T3-T4 242 (48.4 %) 16 (36.4 %) 0.1253 N1a-N1ab 299 (59.8 %) 3 (6.8 %) 0.0000 M1 68 (13.6 %) 1 (2.3 %) 0.0304 Intra-thyroid invasion 297 (79.4 %) 15 (34.1 %) 0.0000 Multifocal growth 93 (18.6 %) 1 (2.3 %) 0.0304 Intra-thyroid invasion 216 (43.2 %) 0 (0.0 %) 0.0304 Multifocal growth 93 (18.6 %) 1 (2.3 %) 0.0304 II 68 (13.6 %) 1 (2.3 %) 0.0304 Patients of 19-40 years n=1991 n=121 0.0304 Tumors above 20 mm 659 (33.1 %)* 80 (66.1 %) 0.0000 M1 43 (2.2 %)* 10 (0.0 %) 0.0000 M1 43 (2.2 %)* 10 (0.0 %) 0.0000 Multifocal growth 346 (17.4 %) 10 (8.3 %) 0.0001 Multifocal growth 346 (17.4 %) 10 (8.8 %) 0.5276 Patients of 1I 53 (2.7 %)* 1 (0.8 %) 0.5276 Patients of y n=1846 n=273<		n=500	n=44	value			
N1a-N1ab299 (59.8 %)3 (6.8 %)0.0000M168 (13.6 %)1 (2.3 %)0.0304Intra-thyroid invasion216 (43.2 %)0 (0.0 %)0.0000Multifocal growth93 (18.6 %)1 (2.3 %)0.0000Disease stage: I432 (86.4 %)43 (97.7 %)0.0304II68 (13.6 %)1 (2.3 %)0.0304Patients of 19-40 yearsn=1991n=121Tumors above 20 mm659 (33.1 %)*80 (66.1 %)0.0000Category: T3-T4560 (28.1 %)*39 (32.2 %)0.3307Na1-N1ab826 (41.5 %)*17 (14.0 %)0.0000M143 (2.2 %)*0 (0.0 %)0.1024Intra-thyroid invasion1339 (67.3 %)*57 (47.1 %)0.0001Multifocal growth346 (17.4 %)10 (8.3 %)0.0093Disease stage: I1938 (97.3 %)*1 (0.8 %)0.2142Mortality5 (0.3 %)1 (0.8 %)0.5276Patients of 41-60 yearsn=1846n=273Tumors above 20 mm480 (26.0 %)*90 (33.0 %)*0.0154Category: T3-T4365 (19.8 %)*61 (22.3 %)*0.3223N1a-N1ab451 (24.4 %)*40 (14.7 %)0.3223M1-8 (0.4 %)*8 (2.9 %)100 (43.3 %)0.0181Extra-thyroid invasion294 (15.9 %)*40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*165 (60.4 %)*0.1961II166 (9.0 %)*40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*36 (40.0 %)	Tumors above 20 mm	236 (47.2 %)	34 (77.3 %)	0.0001			
M168 (13.6 %)1 (2.3 %)0.0304Intra-thyroid invasion397 (79.4 %)15 (34.1 %)0.0000Extra-thyroid invasion216 (43.2 %)0 (0.0 %)0.0000Multifocal growth93 (18.6 %)1 (2.3 %)0.0304II68 (13.6 %)1 (2.3 %)0.0304Patients of $19-40$ years $n=1991$ $n=121$ Tumors above 20 mm659 (33.1 %)*80 (66.1 %)0.0000Category: T3-T4560 (28.1 %)*39 (32.2 %)0.3307Na1-N1ab826 (41.5 %)*17 (14.0 %)0.0000M143 (2.2 %)*0 (0.0 %)0.1024Intra-thyroid invasion1339 (67.3 %)*57 (47.1 %)0.0001Multifocal growth346 (17.4 %)10 (8.3 %)0.0093Disease stage: I1938 (97.3 %)*1 (0.8 %)0.2142Mortality5 (0.3 %)1 (0.8 %)0.2142Mortality5 (0.3 %)1 (0.8 %)0.2223N1a-N1ab451 (24.4 %)*40 (14.7 %)0.0003M18 (0.4 %)*8 (2.9 %)0.0000Intra-thyroid invasion294 (15.9 %)*110 (40.3 %)0.0154Category: T3-T4365 (19.8 %)*61 (22.3 %)*0.2389Disease stage: I1190 (64.4 %)*40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*10 (3.7 %)0.0017III262 (14.2 %)*40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*26 (40.0 %)0.2434Mortality17 (0.9 %)*36 (40.0 %)<	Category: T3-T4	242 (48.4 %)	16 (36.4 %)	0.1253			
Intra-thyroid invasion $397 (79.4 \%)$ $15 (34.1 \%)$ 0.0000 Extra-thyroid invasion $216 (43.2 \%)$ $0 (0.0 \%)$ 0.0000 Multifocal growth $93 (18.6 \%)$ $1 (2.3 \%)$ 0.00060 Disease stage: I $432 (86.4 \%)$ $43 (97.7 \%)$ 0.0304 II $68 (13.6 \%)$ $1 (2.3 \%)$ 0.0304 Patients of $n=1991$ $n=121$ Tumors above 20 mm $659 (33.1 \%)^*$ $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)^*$ $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)^*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)^*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)^*$ $57 (47.1 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0003 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.5276 Patients of $41-60$ years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \psi)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $8 (2.9 \%)$ 0.0001 III $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $262 (14.2 \%)^*$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%^*)$ 0.9961 III <td>N1a-N1ab</td> <td>299 (59.8 %)</td> <td>3 (6.8 %)</td> <td>0.0000</td>	N1a-N1ab	299 (59.8 %)	3 (6.8 %)	0.0000			
Extra-thyroid invasion $216 (43.2 \%)$ $0 (0.0 \%)$ 0.0000 Multifocal growth93 (18.6 %) $1 (2.3 \%)$ 0.0060 Disease stage: I $432 (86.4 \%)$ $43 (97.7 \%)$ 0.0304 II68 (13.6 %) $1 (2.3 \%)$ 0.0304 <i>Patients of</i> $19-40 years$ $n=1991$ $n=121$ Tumors above 20 mm659 (33.1 %)* $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)*$ $39 (32.2 \%)$ 0.3307 Ma1-N1ab $826 (41.5 \%)*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)*$ $57 (47.1 \%)$ 0.0000 Extra-thyroid invasion $443 (22.3 \%)*$ $9 (7.4 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)*$ $120 (99.2 \%)$ 0.560 II $53 (2.7 \%)*$ $1 (0.8 \%)$ 0.5276 Patients of $41-60 years$ $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)*$ $90 (33.0 \%)*$ 0.0154 Category: T3-T4 $365 (19.8 \%)*$ $61 (22.3 \%)*$ 0.3223 N1a-N1ab $451 (24.4 \%)*$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)*$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)*$ $10 (3.7 \%)$ 0.0011 HII $262 (14.2 \%)*$ $40 (14.7 \%)*$ 0.2893 Disease stage: I $1190 (64.4 \%)*$ $10 (10.3 \%)$ 0.0171 <td< td=""><td>M1</td><td>68 (13.6 %)</td><td>1 (2.3 %)</td><td>0.0304</td></td<>	M1	68 (13.6 %)	1 (2.3 %)	0.0304			
Multifocal growth 93 (18.6 %) 1 (2.3 %) 0.0060 Disease stage: I 432 (86.4 %) 43 (97.7 %) 0.0304 II 68 (13.6 %) 1 (2.3 %) 0.0304 Patients of 19-40 years n=1991 n=121 Tumors above 20 mm 659 (33.1 %)* 80 (66.1 %) 0.0000 Category: T3-T4 560 (28.1 %)* 39 (32.2 %) 0.3307 Na1-N1ab 826 (41.5 %)* 17 (14.0 %) 0.0000 M1 43 (2.2 %)* 0 (0.0 %) 0.1024 Intra-thyroid invasion 433 (22.3 %)* 9 (7.4 %) 0.0001 Extra-thyroid invasion 443 (22.3 %)* 9 (7.4 %) 0.0001 Multifocal growth 346 (17.4 %) 10 (8.3 %) 0.02142 Mortality 5 (0.3 %) 1 (0.8 %) 0.5276 Patients of 41-60 years n=1846 n=273 0.0003 Tumors above 20 mm 480 (26.0 %)* 90 (33.0 %)* 0.3223 N1a-N1ab 451 (24.4 %)* 40 (14.7 %) 0.00003 M1 8 (0.4 %)* 8 (2.9 %) <td>Intra-thyroid invasion</td> <td>397 (79.4 %)</td> <td>15 (34.1 %)</td> <td>0.0000</td>	Intra-thyroid invasion	397 (79.4 %)	15 (34.1 %)	0.0000			
Disease stage: 1 $432 (86.4 \%)$ $43 (97.7 \%)$ 0.0304 II68 (13.6 \%)1 (2.3 %) 0.0304 Patients of 19-40 years $n=1991$ $n=121$ Tumors above 20 mm659 (33.1 %)*80 (66.1 %) 0.0000 Category: T3-T4560 (28.1 %)*39 (32.2 %) 0.3307 Na1-N1ab826 (41.5 %)*17 (14.0 %) 0.0000 M143 (2.2 %)*0 (0.0 %) 0.1024 Intra-thyroid invasion1339 (67.3 %)*57 (47.1 %) 0.0000 Extra-thyroid invasion443 (22.3 %)*9 (7.4 %) 0.0003 Disease stage: 11938 (97.3 %)*120 (99.2 %) 0.0560 II53 (2.7 %)*1 (0.8 %) 0.2142 Mortality5 (0.3 %)1 (0.8 %) 0.2142 Mortality5 (0.9 %)*90 (33.0 %)* 0.0154 Category: T3-T4365 (19.8 %)*61 (22.3 %)* 0.3223 N1a-N1ab451 (24.4 %)*40 (14.7 %) 0.3934 M18 (0.4 %)*8 (2.9 %) 0.0000 Intra-thyroid invasion294 (15.9 %)*40 (14.7 %) 0.2893 Disease stage: I1190 (64.4 %)*165 (60.4 %)* 0.961 II166 (9.0 %)*41 (15.0 %)* $0.$	Extra-thyroid invasion	216 (43.2 %)	0 (0.0 %)	0.0000			
II $68 (13.6 \%)$ $1 (2.3 \%)$ 0.0304 Patients of 19-40 years $n=1991$ $n=121$ Tumors above 20 mm $659 (33.1 \%)$ * $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)$ * $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)$ * $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)$ * $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)$ * $57 (47.1 \%)$ 0.0000 Extra-thyroid invasion $443 (22.3 \%)$ * $9 (7.4 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)$ * $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)$ * $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of $41-60$ years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)$ * $90 (33.0 \%)$ * 0.0154 Category: T3-T4 $365 (19.8 \%)$ * $61 (22.3 \%)$ * 0.3223 N1a-N1ab $451 (24.4 \%)$ * $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)$ * $165 (60.4 \%)$ * 0.94394 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)$ * $10 (3.7 \%)$ 0.0001 III $262 (14.2 \%)$ * $36 (40.0 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9$	Multifocal growth	93 (18.6 %)	1 (2.3 %)	0.0060			
Patients of 19-40 years $n=1991$ $n=121$ Tumors above 20 mm $659 (33.1 \%)^*$ $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)^*$ $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)^*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)^*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)^*$ $57 (47.1 \%)$ 0.0000 Extra-thyroid invasion $443 (22.3 \%)^*$ $9 (7.4 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of 41-60 years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.00161 Intra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.2434 Mortality $17 (29.9 \%)^*$ $10 (3.7 \%)$ 0.2434 Multifocal growth $318 (17.2 \%)^*$ $40 (14.7 \%)^*$ 0.8394 IV $228 (12.4 \%)^*$ $27 (9.9 \%)$ 0.2434 <td>Disease stage: I</td> <td>432 (86.4 %)</td> <td>43 (97.7 %)</td> <td>0.0304</td>	Disease stage: I	432 (86.4 %)	43 (97.7 %)	0.0304			
19-40 years $n=1991$ $n=121$ Tumors above 20 mm $659 (33.1 \%)^*$ $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)^*$ $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)^*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)^*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)^*$ $57 (47.1 \%)$ 0.0000 Extra-thyroid invasion $443 (22.3 \%)^*$ $9 (7.4 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of 41-60 years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0010 Intra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $10 (3.7 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.2434 Mortality $17 (26.4 \%)^*$ $20 (22.9 \%)$ 0.2434 Mortality $17 (26.4 \%)^*$ $20 (22.9 \%)$ 0.2435 N1a-N1ab <td< td=""><td>II</td><td>68 (13.6 %)</td><td>1 (2.3 %)</td><td>0.0304</td></td<>	II	68 (13.6 %)	1 (2.3 %)	0.0304			
Tumors above 20 mm $659 (33.1 \%)^*$ $80 (66.1 \%)$ 0.0000 Category: T3-T4 $560 (28.1 \%)^*$ $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)^*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)^*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)^*$ $57 (47.1 \%)$ 0.00001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of 41-60 years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0011 Intra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.1181 Extra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.0171 III $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0283 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.1961 II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0243 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 III $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $36 (40.0 \%)$ 0.2455 N1a-		n=1991	n=121				
Category: T3-T4 $560 (28.1 \%)^*$ $39 (32.2 \%)$ 0.3307 Na1-N1ab $826 (41.5 \%)^*$ $17 (14.0 \%)$ 0.0000 M1 $43 (2.2 \%)^*$ $0 (0.0 \%)$ 0.1024 Intra-thyroid invasion $1339 (67.3 \%)^*$ $57 (47.1 \%)$ 0.00001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of 41-60 years $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0017 Intra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.1961 II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0017 III $262 (14.2 \%)^*$ $36 (40.0 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.00543 M1 $9 (1.9 \%)^*$ $20 (22.2 \%)$ 0.8354 Intra-thyroid $126 (26.2 $		659 (33.1 %)*	80 (66.1 %)	0.0000			
Na1-N1ab 826 (41.5 %)* 17 (14.0 %) 0.0000 M1 43 (2.2 %)* 0 (0.0 %) 0.1024 Intra-thyroid invasion 1339 (67.3 %)* 57 (47.1 %) 0.0000 Extra-thyroid invasion 443 (22.3 %)* 9 (7.4 %) 0.0001 Multifocal growth 346 (17.4 %) 10 (8.3 %) 0.0093 Disease stage: I 1938 (97.3 %)* 120 (99.2 %) 0.0560 II 53 (2.7 %)* 1 (0.8 %) 0.2142 Mortality 5 (0.3 %) 1 (0.8 %) 0.5276 Patients of 41-60 years n=1846 n=273 Tumors above 20 mm 480 (26.0 %)* 90 (33.0 %)* 0.0154 Category: T3-T4 365 (19.8 %)* 61 (22.3 %)* 0.3223 N1a-N1ab 451 (24.4 %)* 40 (14.7 %) 0.0000 Intra-thyroid invasion 294 (15.9 %)* 42 (15.4 %)* 0.8190 Multifocal growth 318 (17.2 %) 40 (14.7 %) 0.2893 Disease stage: I 1190 (64.4 %)* 165 (60.4 %)* 0.1819 III <td< td=""><td></td><td></td><td></td><td></td></td<>							
M143 $(2.2 \%)^*$ 0 (0.0%) 0.1024Intra-thyroid invasion1339 $(67.3 \%)^*$ 57 (47.1%) 0.0000Extra-thyroid invasion443 $(22.3 \%)^*$ 9 (7.4%) 0.0001Multifocal growth346 (17.4%) 10 (8.3%) 0.0093Disease stage: I1938 $(97.3 \%)^*$ 120 (99.2%) 0.0560II53 $(2.7 \%)^*$ 1 (0.8%) 0.2142Mortality5 (0.3%) 1 (0.8%) 0.5276Patients ofn=1846n=273Tumors above 20 mm480 $(26.0 \%)^*$ 90 $(33.0 \%)^*$ 0.0154Category: T3-T4365 $(19.8 \%)^*$ 61 $(22.3 \%)^*$ 0.3223N1a-N1ab451 $(24.4 \%)^*$ 40 (14.7%) 0.0000Intra-thyroid invasion885 $(47.9 \%)^*$ 110 (40.3%) 0.0181Extra-thyroid invasion294 $(15.9 \%)^*$ 42 $(15.4 \%)^*$ 0.8190Multifocal growth318 (17.2%) 40 $(14.7 \%)^*$ 0.8293Disease stage: I1190 $(64.4 \%)^*$ 165 $(60.4 \%)^*$ 0.1243III262 $(14.2 \%)^*$ 40 $(14.7 \%)^*$ 0.8394IV228 (12.4%) 27 (9.9%) 0.2434Mortality17 $(0.9 \%)^*$ 10 (3.7%) 0.0001Patients above 20 mm162 $(33.7 \%)^*$ 36 (40.0%) 0.2475Category: T3-T4127 $(26.4 \%)^*$ 29 (32.2%) 0.2555N1a-N1ab126 (26.2%) 15 (16.7%) 0.0543M19 $(1.9 \%)^*$ 20 (22.2%) 0.8854Extra-thyroid invasion111 $(23$							
Intra-thyroid invasion1339 (67.3 %)* $57 (47.1 %)$ 0.0000Extra-thyroid invasion443 (22.3 %)*9 (7.4 %)0.0001Multifocal growth346 (17.4 %)10 (8.3 %)0.0093Disease stage: I1938 (97.3 %)*120 (99.2 %)0.0560II53 (2.7 %)*1 (0.8 %)0.2142Mortality5 (0.3 %)1 (0.8 %)0.5276Patients ofn=1846n=273Tumors above 20 mm480 (26.0 %)*90 (33.0 %)*0.0154Category: T3-T4365 (19.8 %)*61 (22.3 %)*0.3223N1a-N1ab451 (24.4 %)*40 (14.7 %)0.0000M18 (0.4 %)*8 (2.9 %)0.0010Intra-thyroid invasion294 (15.9 %)*110 (40.3 %)0.0181Extra-thyroid invasion294 (15.9 %)*42 (15.4 %)*0.2893Disease stage: I1190 (64.4 %)*165 (60.4 %)*0.1961II166 (9.0 %)*41 (15.0 %)*0.0017III262 (14.2 %)*40 (14.7 %)0.8394IV228 (12.4 %)27 (9.9 %)0.2434Mortality17 (0.9 %)*10 (3.7 %)0.0001Patients above 60n=481n=90Tumors above 20 mm162 (23.7 %)*36 (40.0 %)0.2475Category: T3-T4127 (26.4 %)*29 (32.2 %)0.2555N1a-N1ab126 (26.2 %)15 (16.7 %)0.0543M19 (1.9 %)*2 (2.2 %)0.8351Intra-thyroid111 (23.1 %)*20 (22.2 %)0.8595Disease stage:				0.1024			
Extra-thyroid invasion $443 (22.3 \%)^*$ $9 (7.4 \%)$ 0.0001 Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0100 Intra-thyroid invasion $294 (15.9 \%)^*$ $41 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.1961 II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $262 (14.2 \%)^*$ $40 (14.7 \%)^*$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162 (26.2 \%)$ $15 (16.7 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.3854 Intra-thyroid $127 (26.4 \%)^*$ $20 (22.2 \%)$	Intra-thyroid invasion			0.0000			
Multifocal growth $346 (17.4 \%)$ $10 (8.3 \%)$ 0.0093 Disease stage: I $1938 (97.3 \%)^*$ $120 (99.2 \%)$ 0.0560 II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0000 Intra-thyroid invasion $294 (15.9 \%)^*$ $410 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ $0,1961$ II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162 (23.7 \%)^*$ $36 (40.0 \%)$ 0.2475 Category: T3-T4 $127 (26.4 \%)^*$ $29 (32.2 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.0543 M1 $9 (1.9 \%)^*$ $20 (22.2 \%)$ 0.8351 Intra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.8351 Intra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.3854 Extra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.3854 III $58 (12.1 \%)^*$ <td>Extra-thyroid invasion</td> <td></td> <td>9 (7.4 %)</td> <td>0.0001</td>	Extra-thyroid invasion		9 (7.4 %)	0.0001			
Disease stage: I1938 (97.3 %)*120 (99.2 %)0.0560II53 (2.7 %)*1 (0.8 %)0.2142Mortality5 (0.3 %)1 (0.8 %)0.5276Patients ofn=1846n=273Tumors above 20 mm480 (26.0 %)*90 (33.0 %)*0.0154Category: T3-T4365 (19.8 %)*61 (22.3 %)*0.3223N1a-N1ab451 (24.4 %)*40 (14.7 %)0.0003M18 (0.4 %)*8 (2.9 %)0.0000Intra-thyroid invasion294 (15.9 %)*42 (15.4 %)*0.8190Multifocal growth318 (17.2 %)40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*165 (60.4 %)*0.1961II166 (9.0 %)*41 (15.0 %)*0.0017III262 (14.2 %)*40 (14.7 %)*0.8394IV228 (12.4 %)27 (9.9 %)0.2434Mortality17 (0.9 %)*10 (3.7 %)0.0001Patients above 60n=481n=90Tumors above 20 mm162 (33.7 %)*36 (40.0 %)0.2475Category: T3-T4126 (26.2 %)15 (16.7 %)0.0543M19 (1.9 %)*2 (2.2 %)0.8351Intra-thyroidinvasion111 (23.1 %)*20 (22.2 %)0.8595Disease stage: I241 (50.1 %)*47 (52.2 %)*0.7122II58 (12.1 %)*10 (11.%)0.7990III73 (15.2 %)20 (22.2 %)0.0866IV109 (22.7 %)*13 (14.4 %)0.0809		346 (17.4 %)		0.0093			
II $53 (2.7 \%)^*$ $1 (0.8 \%)$ 0.2142 Mortality $5 (0.3 \%)$ $1 (0.8 \%)$ 0.5276 Patients of $41-60 years$ $n=1846$ $n=273$ Tumors above 20 mm $480 (26.0 \%)^*$ $90 (33.0 \%)^*$ 0.0154 Category: T3-T4 $365 (19.8 \%)^*$ $61 (22.3 \%)^*$ 0.3223 N1a-N1ab $451 (24.4 \%)^*$ $40 (14.7 \%)$ 0.0003 M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0000 Intra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.1017 III $262 (14.2 \%)^*$ $40 (14.7 \%)^*$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162 (33.7 \%)^*$ $36 (40.0 \%)$ 0.2475 Category: T3-T4 $127 (26.4 \%)^*$ $29 (32.2 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.0543 M1 $9 (1.9 \%)^*$ $2 (2.2 \%)$ 0.8351 Intra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.8595 Disease stage: I $241 (50.1 \%)^*$ $47 (52.2 \%)^*$ 0.7122 II $58 (12.1 \%)^*$ $10 (11. \%)$ 0.7990 III $73 (15.2 \%)$ $20 (22.2 \%)$ 0.0966 IV $109 (22.7 \%)^*$ $13 (14.4 \%)$ <t< td=""><td></td><td></td><td>. ,</td><td>0.0560</td></t<>			. ,	0.0560			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$				0.2142			
Patients of 41-60 yearsn=1846n=273Tumors above 20 mm480 (26.0 %)*90 (33.0 %)*0.0154Category: T3-T4365 (19.8 %)*61 (22.3 %)*0.3223N1a-N1ab451 (24.4 %)*40 (14.7 %)0.0003M18 (0.4 %)*8 (2.9 %)0.0000Intra-thyroid invasion885 (47.9 %)*110 (40.3 %)0.0181Extra-thyroid invasion294 (15.9 %)*42 (15.4 %)*0.8190Multifocal growth318 (17.2 %)40 (14.7 %)0.2893Disease stage: I1190 (64.4 %)*165 (60.4 %)*0,1961II166 (9.0 %)*41 (15.0 %)*0.0017III262 (14.2 %)*40 (14.7 %)*0.8394IV228 (12.4 %)27 (9.9 %)0.2434Mortality17 (0.9 %)*10 (3.7 %)0.0001Patients above 60n=481n=90Tumors above 20 mm162 (33.7 %)*36 (40.0 %)0.2475Category: T3-T4127 (26.4 %)*29 (32.2 %)0.2555N1a-N1ab126 (26.2 %)15 (16.7 %)0.0543M19 (1.9 %)*2 (2.2 %)0.8351Intra-thyroid invasion227 (47.2 %)38 (42.2 %)0.3854Extra-thyroid invasion111 (23.1 %)*20 (22.2 %)0.8595Disease stage: I241 (50.1 %)*10 (11.%)0.7990III58 (12.1 %)*10 (11.%)0.7990III73 (15.2 %)20 (22.2 %)0.0966IV109 (22.7 %)*13 (14.4 %)0.0809	Mortality	. ,					
41-60 years 0 <th0< th=""> 0 <th0< td=""><td></td><td></td><td></td><td></td></th0<></th0<>							
Category: T3-T4 $365(19.8\%)^*$ $61(22.3\%)^*$ 0.3223 N1a-N1ab $451(24.4\%)^*$ $40(14.7\%)$ 0.0003 M1 $8(0.4\%)^*$ $8(2.9\%)$ 0.0000 Intra-thyroid invasion $885(47.9\%)^*$ $110(40.3\%)$ 0.0181 Extra-thyroid invasion $294(15.9\%)^*$ $42(15.4\%)^*$ 0.8190 Multifocal growth $318(17.2\%)$ $40(14.7\%)$ 0.2893 Disease stage: I $1190(64.4\%)^*$ $165(60.4\%)^*$ $0,1961$ II $166(9.0\%)^*$ $41(15.0\%)^*$ 0.0017 III $262(14.2\%)^*$ $40(14.7\%)^*$ 0.8394 IV $228(12.4\%)$ $27(9.9\%)$ 0.2434 Mortality $17(0.9\%)^*$ $10(3.7\%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162(33.7\%)^*$ $36(40.0\%)$ 0.2475 Category: T3-T4 $127(26.4\%)^*$ $29(32.2\%)$ 0.2555 N1a-N1ab $126(26.2\%)$ $15(16.7\%)$ 0.0543 M1 $9(1.9\%)^*$ $2(2.2\%)$ 0.8351 Intra-thyroid invasion $227(47.2\%)$ $38(42.2\%)$ 0.3854 Extra-thyroid invasion $111(23.1\%)^*$ $20(22.2\%)$ 0.3854 Extra-thyroid invasion $111(23.1\%)^*$ $20(22.2\%)$ 0.7122 II $58(12.1\%)^*$ $10(11.\%)$ 0.7990 III $73(15.2\%)$ $20(22.2\%)$ 0.9066 IV $109(22.7\%)^*$ $13(14.4\%)$ 0.0809	41–60 years	n=1846	n=2/3				
N1a-N1ab 451 (24.4 %)* 40 (14.7 %) 0.0003 M1 8 (0.4 %)* 8 (2.9 %) 0.0000 Intra-thyroid invasion 285 (47.9 %)* 110 (40.3 %) 0.0181 Extra-thyroid invasion 294 (15.9 %)* 42 (15.4 %)* 0.8190 Multifocal growth 318 (17.2 %) 40 (14.7 %) 0.2893 Disease stage: I 1190 (64.4 %)* 165 (60.4 %)* 0,1961 II 166 (9.0 %)* 41 (15.0 %)* 0.0017 III 262 (14.2 %)* 40 (14.7 %)* 0.8394 IV 228 (12.4 %) 27 (9.9 %) 0.2434 Mortality 17 (0.9 %)* 10 (3.7 %) 0.0001 Patients above 60 n=481 n=90 10 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2455 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8354 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* <	Tumors above 20 mm	480 (26.0 %)*	90 (33.0 %)*	0.0154			
M1 $8 (0.4 \%)^*$ $8 (2.9 \%)$ 0.0000 Intra-thyroid invasion $885 (47.9 \%)^*$ $110 (40.3 \%)$ 0.0181 Extra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ 0.1961 II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $262 (14.2 \%)^*$ $40 (14.7 \%)^*$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162 (33.7 \%)^*$ $36 (40.0 \%)$ 0.2475 Category: T3-T4 $127 (26.4 \%)^*$ $29 (32.2 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.0543 M1 $9 (1.9 \%)^*$ $2 (2.2 \%)$ 0.8351 Intra-thyroid invasion $227 (47.2 \%)$ $38 (42.2 \%)$ 0.3854 Extra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.8595 Disease stage: I $241 (50.1 \%)^*$ $47 (52.2 \%)^*$ 0.7122 II $58 (12.1 \%)^*$ $10 (11. \%)$ 0.7990 III $73 (15.2 \%)$ $20 (22.2 \%)$ 0.0966 IV $109 (22.7 \%)^*$ $13 (14.4 \%)$ 0.0809	Category: T3-T4	365 (19.8 %)*	61 (22.3 %)*	0.3223			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	N1a-N1ab	451 (24.4 %)*	40 (14.7 %)	0.0003			
Extra-thyroid invasion $294 (15.9 \%)^*$ $42 (15.4 \%)^*$ 0.8190 Multifocal growth $318 (17.2 \%)$ $40 (14.7 \%)$ 0.2893 Disease stage: I $1190 (64.4 \%)^*$ $165 (60.4 \%)^*$ $0,1961$ II $166 (9.0 \%)^*$ $41 (15.0 \%)^*$ 0.0017 III $262 (14.2 \%)^*$ $40 (14.7 \%)^*$ 0.8394 IV $228 (12.4 \%)$ $27 (9.9 \%)$ 0.2434 Mortality $17 (0.9 \%)^*$ $10 (3.7 \%)$ 0.0001 Patients above 60 $n=481$ $n=90$ Tumors above 20 mm $162 (33.7 \%)^*$ $36 (40.0 \%)$ 0.2475 Category: T3-T4 $127 (26.4 \%)^*$ $29 (32.2 \%)$ 0.2555 N1a-N1ab $126 (26.2 \%)$ $15 (16.7 \%)$ 0.0543 M1 $9 (1.9 \%)^*$ $2 (2.2 \%)$ 0.8351 Intra-thyroid invasion $227 (47.2 \%)$ $38 (42.2 \%)$ 0.3854 Extra-thyroid invasion $111 (23.1 \%)^*$ $20 (22.2 \%)$ 0.7122 II $58 (12.1 \%)^*$ $10 (11. \%)$ 0.7990 III $73 (15.2 \%)$ $20 (22.2 \%)$ 0.0966 IV $109 (22.7 \%)^*$ $13 (14.4 \%)$ 0.0809	M1	8 (0.4 %)*	8 (2.9 %)	0.0000			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Intra-thyroid invasion		110 (40.3 %)	0.0181			
Disease stage: I 1190 (64.4 %)* 165 (60.4 %)* 0,1961 II 166 (9.0 %)* 41 (15.0 %)* 0.0017 III 262 (14.2 %)* 40 (14.7 %)* 0.8394 IV 228 (12.4 %) 27 (9.9 %) 0.2434 Mortality 17 (0.9 %)* 10 (3.7 %) 0.0001 Patients above 60 n=481 n=90 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2475 Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Extra-thyroid invasion	294 (15.9 %)*	42 (15.4 %)*	0.8190			
II166 (9.0 %)*41 (15.0 %)*0.0017III262 (14.2 %)*40 (14.7 %)*0.8394IV228 (12.4 %)27 (9.9 %)0.2434Mortality17 (0.9 %)*10 (3.7 %)0.0001Patients above 60n=481n=90Tumors above 20 mm162 (33.7 %)*36 (40.0 %)0.2475Category: T3-T4127 (26.4 %)*29 (32.2 %)0.2555N1a-N1ab126 (26.2 %)15 (16.7 %)0.0543M19 (1.9 %)*2 (2.2 %)0.8351Intra-thyroid invasion227 (47.2 %)38 (42.2 %)0.3854Extra-thyroid invasion111 (23.1 %)*20 (22.2 %)0.8595Disease stage: I241 (50.1 %)*47 (52.2 %)*0.7122II58 (12.1 %)*10 (11. %)0.7990III73 (15.2 %)20 (22.2 %)0.0966IV109 (22.7 %)*13 (14.4 %)0.0809	Multifocal growth		40 (14.7 %)	0.2893			
III 262 (14.2 %)* 40 (14.7 %)* 0.8394 IV 228 (12.4 %) 27 (9.9 %) 0.2434 Mortality 17 (0.9 %)* 10 (3.7 %) 0.0001 Patients above 60 n=481 n=90 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2475 Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Disease stage: I		165 (60.4 %)*	0,1961			
IV 228 (12.4 %) 27 (9.9 %) 0.2434 Mortality 17 (0.9 %)* 10 (3.7 %) 0.0001 Patients above 60 n=481 n=90 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2475 Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	II	166 (9.0 %)*	41 (15.0 %)*	0.0017			
Mortality 17 (0.9 %)* 10 (3.7 %) 0.0001 Patients above 60 n=481 n=90 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2475 Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	III	262 (14.2 %)*	40 (14.7 %)*	0.8394			
Patients above 60 n=481 n=90 Tumors above 20 mm 162 (33.7 %)* 36 (40.0 %) 0.2475 Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	IV	228 (12.4 %)	27 (9.9 %)	0.2434			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Mortality	17 (0.9 %)*	10 (3.7 %)	0.0001			
Category: T3-T4 127 (26.4 %)* 29 (32.2 %) 0.2555 N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Patients above 60	n=481	n=90				
N1a-N1ab 126 (26.2 %) 15 (16.7 %) 0.0543 M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Tumors above 20 mm	162 (33.7 %)*	36 (40.0 %)	0.2475			
M1 9 (1.9 %)* 2 (2.2 %) 0.8351 Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Category: T3-T4			0.2555			
Intra-thyroid invasion 227 (47.2 %) 38 (42.2 %) 0.3854 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	N1a-N1ab			0.0543			
invasion 227 (47.2 %) 38 (42.2 %) 0.3834 Extra-thyroid invasion 111 (23.1 %)* 20 (22.2 %) 0.8595 Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809		9 (1.9 %)*	2 (2.2 %)	0.8351			
Disease stage: I 241 (50.1 %)* 47 (52.2 %)* 0.7122 II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	invasion	227 (47.2 %)	38 (42.2 %)	0.3854			
II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Extra-thyroid invasion	111 (23.1 %)*	20 (22.2 %)	0.8595			
II 58 (12.1 %)* 10 (11. %) 0.7990 III 73 (15.2 %) 20 (22.2 %) 0.0966 IV 109 (22.7 %)* 13 (14.4 %) 0.0809	Disease stage: I	241 (50.1 %)*	47 (52.2 %)*	0.7122			
IV 109 (22.7 %)* 13 (14.4 %) 0.0809	II	58 (12.1 %)*	10 (11. %)	0.7990			
IV 109 (22.7 %)* 13 (14.4 %) 0.0809	III	73 (15.2 %)	20 (22.2 %)	0.0966			
Mortality 36 (7.5 %)* 12 (13,3 %)* 0.0304	IV	109 (22.7 %)*	13 (14.4 %)	0.0809			
	Mortality	36 (7.5 %)*	12 (13,3 %)*	0.0304			

Note: * - < 0.01 vs. the previous age group

As the body ages (19-60 years), the frequency of large tumors as well as tumors of T3-T4 categories becomes lower; however, this index remains higher in FTC patients (Table 4). Simultaneously, among these patients the percent of multifocal tumors gradually increases, although this index and the frequency of tumors with intra- and extra-thyroid invasion is lower than in PTC cases. Besides, distant metastases were found more often in FTC patients of 41–60 years comparing to PTC ones. Therefore, among the absolute majority of patients of 19–40 years, the I disease stage is detected; in patients of 41–60 years this percent is significantly lower, but it is not different for these carcinoma types. The patients mortality (especially among FTC ones) is higher among PTC as well as among FTC patients is decreased (Table 2).

The lowest survival level is detected among patients above 60. Should be noted the wide-spreading of large tumors, tumors of T3-T4 categories, multifocal neoplasms as well as those of extra-thyroid invasion and distant metastases concerns only PTC patients; it is less seen in FTC cases. The disease stages I or II have been found in 60 % of thyroid carcinoma cases. No significant difference pertaining the wide-spreading of PTC and FTC with different properties has been registered among patients above 60, the mortality of FTC patients above 60 being, however, the highest (Table 4).

The worse prognosis for FTC patients may be also due to different biological characteristics of tumors. For instance, the analysis of cumulative patients survival depending on the tumor size demonstrates in cases of microcarcinoma the survival dynamics during the observation term is the same for both PTC and FTC patients; however, if the tumor size increases, the dynamics becomes worse for PTC patients and still more unfavorable for FTC ones (Table 5).

The analysis of possible causes leading to decreased survival of patients depending on the tumor size suggests the percent of patients with metastatic carcinoma becomes higher (especially for PTC belonging to the N1ab category and FTC of N1a and N1b categories) according to the increased tumor sizes (Table 6). The percent of PTC patients with multifocal tumor growth and intra- or extra-thyroid invasion becomes also higher. Such dynamics rate is lower pertaining the percent of FTC patients, the mortality level of patients becoming, however, increased namely among FTC ones when the tumor size becomes larger.

Table 5

Papillary carcinoma								ular carcir		,
Groups		survival term, years survival term, years							Desites	
	2	5	10	20	P _L -value	2	5	10	20	P _L -value
			·	tun	ior size					•
<10 mm	100	100	100	100		100	100	100	100	
11–20 mm	99.8	99.6	99.6	99.6	0.000	98.8	98.8	97.9	97.9	0.000
21–40 mm	99.2	98.8	98.1	97.8	0.000	98.8	96.6	94.4	92.8	0.000
>40 mm	94.6	92.6	90.2	89.5		92.9	90.0	82.9	82.9	
	multifocal growth property									
absent	99.6	99.2	99.1	99.1	0.000	98.9	97.6	95.9	95.2	0.002
present	98.3	97.6	96.0	95.2	0.000	92.5	92.5	88.4	-	0.002
				intra-thy	roid invasi	on				
absent	100	99.7	99.5	99.5	0.000	99.0	98.6	97.5	97.5	0.003
present	98.9	98.5	97.8	97.6	0.000	97.0	95.0	91.8	90.5	0.003
				extra-thy	roid invasi	on				
absent	99.9	99.8	99.6	99.6	0.000	99.0	98.8	97.2	97.2	0.000
present	97.2	96.0	94.8	94.1	0.000	93.5	87.8	82.0	78.1	0.000
				Са	tegory					
T1	100	100.0	100	100.0		99.5	99.5	99.5	99.5	
Τ2	100	100.0	100	100.0		100	100	98.0	98.0	
Т3	99.0	99.0	98.0	98.0	0.000	93.5	91.0	86.0	84.0	0.000
T4a	94.0	91.0	90.0	90.0		95.5	86.0	79.0	79.0	
T4b	46.0	29.0	0	0		_	_	_	-	
N0	99.9	99.7	99.4	99.4		99.0	98.4	96.8	96.0	
Nla	99.9	99.8	99.8	99.1	0.000	93.8	90.0	90.0	90.0	0.000
N1b	98.6	98.2	96.6	95.4	0.000	100	100	100	-	0.000
Nab	96.9	95.8	94.7	94.7		90.0	83.4	69.8	69.8	
M0	99.4	99.1	98.8	98.6	0.000	98.5	97.0	96.0	95.5	0.000
M1	97.7	94.9	92.9	91.6	0.000	75.0	75.0	40.0	-	0.000

Cumulative patients survival with papillary and follicular thyroid carcinomas of different biological characters, %

№ 4(31)2019

Table 6

Cohort of thyroid carcinoma patients: frequency of patients with carcinoma of different properties, frequency of disease stages, and mortality among patients with papillary and follicular carcinoma of different sizes, n (%)

Carcinoma Index Carcinoma papillary follicular Px valu Tumor size below 10 mm n=1487 n=122 Category: N1a 175 (11.8 %) 3 (2.5 %) 0.00 N1b 82 (5.5 %) 2 (1.6 %) 0.06 N1ab 80 (5.4 %) 0 (0.0 %) 0.00 M1 8 (0.5 %) 1 (0.8 %) 0.683 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.00 Extra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.000 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.497 Tumor size: 11–20 mm n=1794 n=163 11 (6.7 %) 0.003 N1b 137 (7.6 %)* 4 (2.5 %) 0.014 N1b 137 (7.6 %)* 8 (4.9 %)* 0.003
papillary follicular value Tumor size below 10 mm n=1487 n=122 Category: N1a 175 (11.8 %) 3 (2.5 %) 0.00 N1b 82 (5.5 %) 2 (1.6 %) 0.06 N1ab 80 (5.4 %) 0 (0.0 %) 0.006 M1 8 (0.5 %) 1 (0.8 %) 0.68 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.000 Extra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.000 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 0.000 N1b 137 (7.6 %)* 4 (2.5 %) 0.014
below 10 mm n=1487 n=122 Category: N1a 175 (11.8 %) 3 (2.5 %) 0.00 N1b 82 (5.5 %) 2 (1.6 %) 0.06 N1ab 80 (5.4 %) 0 (0.0 %) 0.00 M1 8 (0.5 %) 1 (0.8 %) 0.68 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.00 Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.00 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 11 (6.7 %) 0.003 N1b 137 (7.6 %)* 4 (2.5 %) 0.014
N1b 82 (5.5 %) 2 (1.6 %) 0.06 N1ab 80 (5.4 %) 0 (0.0 %) 0.009 M1 8 (0.5 %) 1 (0.8 %) 0.68 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.009 Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.009 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.499 Tumor size: 11-20 mm n=1794 n=163 0.009 N1b 137 (7.6 %)* 4 (2.5 %) 0.019
N1ab 80 (5.4 %) 0 (0.0 %) 0.003 M1 8 (0.5 %) 1 (0.8 %) 0.68 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.007 Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.007 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 0.007 N1b 137 (7.6 %)* 4 (2.5 %) 0.014
M1 8 (0.5 %) 1 (0.8 %) 0.68 Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.00' Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.00' Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49' Tumor size: 11–20 mm n=1794 n=163 0.00' N1b 137 (7.6 %)* 4 (2.5 %) 0.01'
Multifocal growth 198 (13.3 %) 6 (4.9 %) 0.00 Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.00 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 0.00 Category: N1a 277 (15.4 %)* 11 (6.7 %) 0.00 N1b 137 (7.6 %)* 4 (2.5 %) 0.01
Intra-thyroid invasion 684 (46.0 %) 6 (29.5 %) 0.00 Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 0.00 Category: N1a 277 (15.4 %)* 11 (6.7 %) 0.00 N1b 137 (7.6 %)* 4 (2.5 %) 0.01
Extra-thyroid invasion 137 (9.2 %) 9 (7.4 %) 0.49 Tumor size: 11–20 mm n=1794 n=163 0.003 Category: N1a 277 (15.4 %)* 11 (6.7 %) 0.003 N1b 137 (7.6 %)* 4 (2.5 %) 0.014
Tumor size: 11–20 mm n=1794 n=163 Category: N1a 277 (15.4 %)* 11 (6.7 %) 0.00 N1b 137 (7.6 %)* 4 (2.5 %) 0.01
Category: N1a 277 (15.4 %)* 11 (6.7 %) 0.004 N1b 137 (7.6 %)* 4 (2.5 %) 0.014
N1b 137 (7.6 %)* 4 (2.5 %) 0.01
N1ab $232(1200/)* 2(100/)* 000$
$ 252(12.970)^{\circ} 8(4.970)^{\circ} 0.000$
M1 29 (1.6 %)* 2 (1.2 %) 0.702
Multifocal growth 331 (18.5 %)* 27 (16.6 %)* 0.55
Intra-thyroid invasion 1127 (62.8 %)* 81 (49.7 %)* 0.00
Extra-thyroid invasion 362 (20.2 %)* 23 (14.1 %) 0.06
Mortality 4 (0.2 %) 3 (1.8 %) 0.00
<i>Tumor size 21–40mm</i> n=1161 n=157
Category: N1a 151 (13.0 %) 11 (7.0 %) 0.03
N1b 103 (8.9 %) 8 (5.1 %) 0.17
N1ab 268 (23.1 %)* 11 (7.0 %) 0.00
M1 60 (5.2 %)* 6 (3.8 %) 0.46
Multifocal growth 248 (21.4 %)* 24 (15.3 %) 0.00
Intra-thyroid invasion 780 (67.2 %)* 68 (43.3 %) 0.00
Extra-thyroid invasion 390 (33.6 %)* 26 (16.6 %) 0.00
Mortality 18 (1.6 %) 8 (5.1 %) 0.00
Tumor size: above 40 mmn=376n=86
Category: N1a 44 (11.7 %) 8 (9.3 %) 0.52
N1b 33 (8.8 %) 6 (7.0 %) 0.58
N1ab 121 (32.2 %)* 6 (7.0 %) 0.00
M1 31 (8.2 %)* 2 (2.3 %) 0.054
Multifocal growth 97 (25.8 %) 9 (10.5 %) 0.002
Intra-thyroid invasion 257 (68.4 %)* 35 (40.7 %) 0.00
Extra-thyroid invasion 175 (46.5 %)* 13 (15.1 %) 0.00
Mortality 32 (8.5 %) 13 (15.1 %) 0.06

Note: * - < 0.01 *vs. the previous group*

In cases of FTC patients, the presence of N1ab category tumor is more negative, the patients survival reaching 100 % in cases of carcinoma belonging to the N1b category (Table 5). PTC intranodal metastases are of lesser impact on the patients' survival comparing to distant ones; in cases of FTC patients with distant metastases the survival level is drastically lower comparing to PTC patients with distant metastases (Table 5).

Multifocal tumor growth is a negative prognostic factor for all patients of our cohort, being however, more important for FTC patients (Table 5), although the percent of such carcinoma is lower comparing with PCT ones (Table 1). The impact of extra-thyroid invasion on prognosis for the cohort patients, especially for FTC ones; in cases of intra-thyroid invasion the prognosis is better, the difference between indices for PTC and FTC patients being, however, kept (Table 5).

Since the neoplasm size and its invasive characters are prognostic factors determining the patient's survival with thyroid carcinoma, it is clear the T category is also prognosis-associated. The survival of PTC patients of T1 and T2 categories reaching 100 %, this trend is less strongly marked, the level of patients survival being, however, high (Table 5). The increase of T category (T3, T4a) makes the survival difference between PTC and FTC patients more perceptible. The worst is prognosis for PTC patients of the T4b category.

The list of important prognostic factors includes also the disease stage. For the cohort patients with the Ist disease stage, the survival level reaches 100 % independently on any histological type of carcinoma (Table 7). At the same time, the increase of the disease stage lead to significant drop of patients survival both in PTC and FTC cases, the most unfavorable prognosis coincides with the stage IVc.

The surgical intervention volume and radio-iodine therapy are also thought to belong to important clinical prognostic factors. The increased aggressiveness of intervention (from total thyroidectomy up to thyroidectomy together with lymph nodes dissection) in accompanied by moderate decrease of PTC patients survival (Table 7). The survival of patients following thyroid resection is intermediate comparing with persons with hemithyroidectomy; this index is lower than in persons following total thyroidectomy. The radio-iodine therapy promotes the survival of PTC patients, this index being, however, is not dependent on the quantity of courses realized. In cases of FTC, any positive radio-iodine therapy effect is absent (Table 7). The relapse presence decreases the survival levels for PTC and FTC patients; the drop of this index becomes especially impetuous in later post-operation terms, this tendency being more manifested in FTC patients comparing to PTC ones (Table 7).

Taking into consideration all the prognostic factors that are able to impact on the survival level of patients with thyroid carcinoma (it is realized, for example, in the MACIS system), it is possible to obtain an integrated index describing the level of patients survival level. According to this index, the survival levels of PTC and FTC patients of the I disease stage having the score quantity below 6, differ insignificantly (Table 7). However, the increase of factors quantity taken for calculation and being unfavorable for prognosis (increase of scores quantity), decreases significantly the patients survival. It is especially clear from the survival level of FTC patients with the score quantity above 8 (III–IV disease stages) whose survival percent during 10 years is as low as 20 % despite the fact that this level for PTC patients is 66 %.

Table 7

	1		Papillary					Follicular	1 1	,
Groups		survival to	erm, years		D 1	survival term, years				
	2	5	10	20	P _L -value	2	5	10	20	$-P_{L}$ -value
					disease stage	2				
Ι	100	100	100	100		100	100	100	100	
II	100	100	98.0	98.0]	98.0	98.0	95.0	95.0	7
III	100	100	97.0	97.0	0.000	91.0	89.0	84.0	77.0	0.000
IVa	96.0	94.0	91.0	88.0	0.000	94.0	85.0	79.0	79.0	0.000
IVb	42.0	22.0	-	-		_	-	-	-	
IVc	61.0	48.0	16.0	0]	71.0	71.0	0	0	
				ор	eration volu	me				
TE	99.7	99.5	99.2	99.2		99.1	98.8	96.0	95.2	
hemiTE	99.1	98.3	97.7	97.7	0.000	98.9	97.6	96.2	96.2	0.000
TE+ dissection	98.3	97.6	96.9	96.4	0.000	89.4	83.0	83.0	83.0	0.000
				radi	io-iodine the	rapy				
not done	98.4	97.5	97.5	97.5	0.006	97.7	96.4	95.1	95.1	0.769
done	99.4	99.1	98.6	98.4	0.000	98.2	97.2	94.8	94.1	0.709
1–3 courses	99.4	99.1	98.6	98.4		98.1	97.1	94.6	93.9	
4-6 courses	100	98.7	98.7	98.7	0.907	100	100	100	100	0.422
> 7 courses	100	100	100	100		_	_	_	_	
					relapse					
absent	99.5	99.2	98.8	98.7	0.000	98.0	97.8	96.0	95.5	0.000
present	98.2	96.0	91.3	91.3	0.000	79.0	79.0	65.0	65.0	0.000
				Λ	ACIS system	m				
< 5.99 scores	100	100	99.8	99.8		100	99.8	98.5	98.5	
6–6.99 scores	99.0	97.2	95.8	95.8	0.000	91.5	86.0	86.0	_	0.000
7–7.99 scores	96.2	94.4	93.0	90.4		93.5	93.5	71.5	_	1
> 8 scores	81.0	74.4	66.2	64.6	1	73.0	58.5	20.0	_	1

Cumulative patients survival with papillary and follicular thyroid carcinoma with different clinical properties, %

Note: TE – *thyroidectomy*

6. Discussion

The obtained results concerning the worse prognosis for FTC patients coincide with the data obtained by other authors, which do conform to the opinion that histological type of thyroid carcinoma is a significant prognostic factor [4, 5]. The causes stipulating for this phenomenon are not still completely understood. Of interest, the opinion on the negative prognosis associated with the FTC diagnosis was refuted in earlier studies [7].

While analyzing the causes supposed to be important for disease prognosis and to impact on the patient's survival of malignant thyroid tumors, the researches examine a lot of factors – patients' age and sex, tumors size and characteristics, volume of operative intervention, and quality of post-operative management. As to the importance of sex as a prognostic factor for PTC patients, this problem is still discussed [1, 2]; the male sex is mostly thought to be unfavorable for prognosis [8–11]. The lower survival level found by us for both sexes of FTC patients comparing to PTC ones is associated with higher frequency of patients with larger in size FTC, although for both types of carcinoma, male sex is a negative prognostic factor.

The analysis of data for 124 FTC patients permitted to conclude that the age belongs to the most important prognostic factors for this type of carcinoma [12]; currently, it is also correct for PTC [8, 10]. According to our data, PTC of large size, metastasis and invasive, are mostly observed in patients below 18 (comparing to elder ones); it meets completely the current ideas on "pediatric" PTC [13]. Simultaneously, aggressive FTC wide-spreading in patients below 18 is significantly lower. It is namely this is a circumstance levels the role of thyroid carcinoma histological type in the survival of patients below 18. The increase of patient's age (up to 60) is accompanied by decreased frequency of PTC sizes above 20 mm as well as tumors with metastases and intra- or extra-thyroid invasion, but not of multifocal ones. It reflects more significantly the levels of both mortality increase and drop of FTC patient's survival. In cases of both PTC and FTC patients, the most unfavorable survival prognostic factor is patient's age

above 60 that coincides with other authors opinion [2, 9, 14] underlining that unsatisfactory therapy results in elderly patients are due to their worsened general condition state as well as to their decreased treatment tolerance. According to our data, among patients above 60 (comparing to patients of 41–60) the frequencies of large PTC as well as of tumors with multifocal growth character begin to increase. As to FTC, there is higher wide-spreading of carcinoma with extra-thyroid invasion, the significance of such changes being, however, not confirmed.

The increase of differentiated thyroid carcinoma sizes is shown to be associated with increased patient's mortality; it is considerable higher in cases of tumor sizes exceeding 40 mm [2]. However, in the available literature there are also data concerning microPT C with aggressive properties, the lesser tumor size being no guarantee of positive prognostic results [15]; simultaneously, it is seen more oft tumors above 10 cm to be more aggressive [16]. Multivariate analysis shows that important factors associated with greater tumor size include tumor histological type, multifocality, extra-thyroid invasion, and distant metastases [17]. The decreased survival levels among PTC patients may be due to increased frequency of more aggressive tumors accompanied by their size increase. In FTC cases the conclusion is not so unambiguous; the cause of more significant drop of these patients survival comparing to PTC ones may be associated with a complex of factors including both increased frequency of aggressive tumors and twice higher relative quantity of elderly (above 60) FTC patients in the cohort (19.7 % of FTC patients and 10 % of PTC ones).

The distribution of patients in groups containing different sizes tumors meets the requirements of the current trend, however recently the authors carry out such distribution using some more lesser steps (10 mm), grouping separately also tumors whose sizes are 41–50 and above 50 mm. It has given a chance to understand the patients 8-years-old survival to be significantly lower namely in cases of tumors above 50 mm [17]. A "barrier" tumor size has been determined (8.5 mm) above which the frequencies of metastases, multifocality or extra-thyroid invasion become higher [18].

We have found that increase of tumor size is accompanied by higher percent of patients with metastatic PTC, this dynamics being less marked in FTC cases. Different conclusions of authors concerning the impact of regional PTC metastasis upon the survival indices "oscillate" from the complete refuse up to recognition. An accurate evaluation of metastasis impact to the survival of patients is thought to be impossible without standardized criteria for lymph node damage stratification [19]. An especially negative circumstance is the presence of extra-nodal invasion decreasing the 10-years survival term of patients from 99 % (without such invasion) to 73 % (in its presence). Such a decrease is found to be more significant in patients of elder age groups [20]. The extra-nodal invasion is associated with more aggressive tumors, distant metastases, and higher mortality of patients [21]. The current approaches aiming to understand the prognostic role of intra-nodal PTC metastases foresee

not only the registration of metastases presence and their localization, bur also the registration of metastatic nodes quantity and the size of the larger among them [22]. Currently the intra-nodal metastases are not thought to be an independent survival prognostic factor. The presence of microscopic damage is associated with a high risk of local relapse, but the role of microscopic metastases is still disputable [19]. It should be emphasized that studies pertaining the prognostic importance of FTC metastasis to lymph nodes are almost absent because of lesser quantity of carcinoma belonging to this histological type and lower frequency of their metastasis to these structures.

The data available on the distant metastasis contribution into the patients survival are significantly different, the 10-year survival term is of wide diapason – from 25 up to 70 % [23, 24]. Such a fact may be due to the presence in the groups analyzed of both PTC and FTC patients (according to our data, the 10-years survival term among FTC patients is twice lower comparing to this index for PTC ones). Besides, a better prognosis is reported for patients whose distant metastases have been found during the disease diagnostic comparing to ones whose distant metastases have been developed on the later stage [23]. The metastases localization is also important for survival prognosis, the metastases of extra-pulmonary localization being "the most negative" [25].

Our results confirm the conclusion attributing the extra-thyroid tumor invasion to negative prognostic markers. This factor has a higher impact on the FTC patient's survival. The survivals of patients with minimally invasive and widely invasive FTC differ almost by two times (97 % and 46 %) [12]. The 100 % survival level is found only for patients below 45 with minimally invasive FTC without vascular invasion. According to other data, the 10-years survival term in cases of widely invasive FTC is by 16 % lower comparing to non-invading ones [5]. Now the problem is discussed on the vascular invasion contribution as the patients survival prognostic factor, while there is already no doubt that in FTC cases the vascular invasion to be an important predictor of distant metastases and necessity of radio-iodine therapy use [26]. Different invasive properties of FTC and PTC may be due to biological characteristics of these carcinoma. The contribution of tumor sizes and extra-thyroid metastases localization for the further disease prognosis is also discussed [27].

The role of multifocal gland damage by tumor is now considered. Thus, multifocal PTC is associated with higher relapse frequency than unifocal one, the survival differences being, however, not significant [28]. Later studies demonstrate the poor prognosis to be mostly associated with tumor size rather than with quantity of tumor foci [29]. According to our data it is exactly this prognostic factor is important.

Discussing the clinical factors, it is necessary to pay attention on a fact that survival of patients following the gland resection is lower comparing to this index for patients after total thyroidectomy. It may be due to higher quantity of later relapses having developed in the residual gland tissue. As the relapse development may be associated with several factors being prognostic ones, but possessing different effect pertaining PTC and FTC, it is a complex problem to analyze the causes of decreased patients survival in cases of thyroid carcinoma belonging to these histological types. The use of radio-iodine therapy increases the survival of PTC patients, but this process, however, is not dependent on the quantity of courses having been carried out. In FTC cases, any positive effect associated with radio-iodine therapy is less pronounced.

Therefore, there are a lot of factors being important both for PTC and FTC prognosis. It is thought every histological type possesses "its own set of independent prognostic factors", only patient sex and volume of surgical intervention being general ones [30]. Our data confirm that all the prognostic factors having been analyzed in our study for both types of thyroid carcinoma are really significant for prognosis. In our opinion, the most important prognosis factor is the neoplasm size, being associated with other ones – metastases development, multifocal growth, intra- and extra-thyroid invasion, relapse development. The patient age and sex are also of great importance.

Together with a lot of generally known prognostic factors (neoplasm size, patient sex, extra-thyroid invasion, distant metastases), other, additional factors should be taken into account to calculate the risks of relapses or death [19]. These factors may be more specific, in particular, in cases of thyroid carcinoma belonging to different histological types.

This study has the following limitations. Not all patients were observed the same amount of time after surgery; some patients had primary surgery at other clinics.

7. Conclusions

1. In patients below 40 with microcarcinoma, without extra-thyroid neoplasm invasion and metastases (T1N0M0 category, I disease stage), the prognosis following thyroidectomy does not depend on the carcinoma type. Under other conditions, the impact of neoplasm histological type (FTC vs PTC) is more important. In some cases (for men, patients above 60, with tumors above 40 mm, with multifocal growth character, with intra- and, especially, extra-thyroid invasion, with distant metastases, in cases of thyroidectomy and lymph node dissection, relapse presence) the neoplasm type becomes significantly more important.

2. The obtained results confirm the conclusion that histological subtype of differentiated thyroid carcinoma is the most important predictor of diseases persistence/ disease relapse or patients mortality.

References

1. Glikson, E., Alon, E., Bedrin, L., Talmi, Y. (2017). Prognostic factors in differentiated thyroid cancer revisited. Israel Medical Association Journal, 19 (2), 114–118.

2. Konturek, A., Barczyński, M., Nowak, W., Richter, P. (2012). Prognostic factors in differentiated thyroid cancer – a 20-year surgical outcome study. Langenbeck's Archives of Surgery, 397 (5), 809–815. doi: http://doi.org/10.1007/s00423-011-0899-z

3. Passler, C., Scheuba, C., Prager, G., Kaczirek, K., Kaserer, K., Zettinig, G., Niederle, B. (2004). Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocrine-Related Cancer, 11, 131–139. doi: http://doi.org/10.1677/erc.0.0110131

4. Gulcelik, M. A., Ozdemir, Y., Kadri Colakoglu, M., Camlibel, M., Alagol, H. (2012). Prognostic factors determining survival in patients with node positive differentiated thyroid cancer: a retrospective cross-sectional study. Clinical Otolaryngology, 37 (6), 460–467. doi: http://doi.org/10.1111/coa.12022

5. Lorea, A. E., Bermejo, I. M., Esparza, N. E., Apinaniz, E. A., Arribas, J. P., Echarri, A. I. et. al. (2018). Clinical characteristics and prognostic factors in patients with follicular thyroid carcinoma. Endocrine Abstracts, 56, 1143. doi: http://doi.org/10.1530/ endoabs.56.p1146

6. Lang, B. H.-H., Lo, C.-Y., Chan, W.-F., Lam, K.-Y., Wan, K.-Y. (2006). Prognostic Factors in Papillary and Follicular Thyroid Carcinoma: Their Implications for Cancer Staging. Annals of Surgical Oncology, 14 (2), 730–738. doi: http://doi.org/10.1245/s10434-006-9207-5

7. Sautter-Bihl, M.-L., Raub, J., Hetzel-Sesterheim, M., Heinze, H. G. (2001). Differentiated Thyroid Cancer: Prognostic Factors and Influence of Treatment on the Outcome in 441 Patients. Strahlentherapie Und Onkologie, 177 (3), 125–131. doi: http://doi.org/10.1007/pl00002392

8. Nitipir, C., Alecu, L., Slavu, I., Tulin, R., Jecan, R., Orlov, C. et. al. (2018). Unmodifiable variables related to thyroid cancer incidence. Journal of Mind and Medical Sciences, 5 (1), 123–128. doi: http://doi.org/10.22543/7674.51.p123128

9. Tang, J., Liu, H. B., Yu, L., Meng, X., Leng, S. X., Zhang, H. (2018). Clinical-pathological Characteristics and Prognostic Factors for Papillary Thyroid Microcarcinoma in the Elderly. Journal of Cancer, 9 (2), 256–262. doi: http://doi.org/10.7150/jca.22700

10. Kauffmann, R. M., Hamner, J. B., Ituarte, P. H. G., Yim, J. H. (2018). Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: should there be three age categories for staging? BMC Cancer, 18 (1). doi: http:// doi.org/10.1186/s12885-018-4181-4

11. Santrac, N., Markovic, I., Goran, M., Buta, M., Djurisic, I., Dzodic, R. (2017). Prognostic factors for intrathyroidal papillary carcinomas – a multivariate analysis. Endocrine Abstracts, 49. doi: http://doi.org/10.1530/endoabs.49.gp225

12. O'Neill, C. J., Vaughan, L., Learoyd, D. L., Sidhu, S. B., Delbridge, L. W., Sywak, M. S. (2011). Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. European Journal of Surgical Oncology, 37 (2), 181–185. doi: http://doi.org/10.1016/j.ejso.2010.11.005

13. Azhar, Y., Achmad, D., Lukman, K., Hilmanto, D. (2018). Pediatric differentiated thyroid carcinoma risk factor for analysis for disease free survival. Indian Journal of Medical and Paediatric Oncology, 39 (2), 153–158. doi: http://doi.org/10.4103/ijmpo. jjmpo_70_17 14. Ito, Y., Miyauchi, A., Kihara, M., Fukushima, M., Higashiyama, T., Miya, A. (2018). Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. World Journal of Surgery, 42 (3), 615–622. doi: http://doi.org/10.1007/s00268-018-4479-z

15. Barbaro, D., Simi, U., Meucci, G., Lapi, P., Orsini, P., Pasquini, C. (2005). Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers – are they different diseases? Clinical Endocrinology, 63 (5), 577–581. doi: http://doi.org/10.1111/j.1365-2265.2005.02386.x

16. Gomez, N. R., Kouniavsky, G., Tsai, H.-L., Somervell, H., Pai, S. I., Tufano, R. P. et. al. (2011). Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer. Journal of Surgical Oncology, 104 (6), 613–616. doi: http://doi.org/10.1002/jso.21891

17. Qu, N., Shi, R., Yang, S., Ma, B., Lu, Z., Wen, D. et. al. (2016). Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model. OncoTargets and Therapy, 9, 5015–5022. doi: http://doi.org/10.2147/ ott.s107187

18. Gong, Y., Li, G., Lei, J., You, J., Jiang, K., Li, Z. et. al. (2018). A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. Cancer Management and Research, 10, 899–906. doi: http://doi.org/10.2147/cmar. s154135

19. Gillanders, S. L., O'Neill, J. P. (2018). Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC). European Journal of Surgical Oncology, 44 (3), 286–296. doi: http://doi.org/10.1016/j.ejso.2017.07.013

20. Wu, M.-H., Shen, W. T., Gosnell, J., Duh, Q.-Y. (2014). Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Head & Neck, 37 (9), 1336–1343. doi: http://doi.org/10.1002/hed.23747

21. Lango, M., Flieder, D., Arrangoiz, R., Veloski, C., Yu, J. Q., Li, T. et. al. (2013). Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid, 23 (9), 1099–1105. doi: http://doi.org/10.1089/thy.2013.0027

22. Lamartina, L., Grani, G., Durante, C., Filetti, S. (2018). Recent advances in managing differentiated thyroid cancer. F1000Research, 7, 86. doi: http://doi.org/10.12688/f1000research.12811.1

23. Wang, L. Y., Palmer, F. L., Nixon, I. J., Thomas, D., Patel, S. G., Shaha, A. R. et. al. (2014). Multi-Organ Distant Metastases Confer Worse Disease-Specific Survival in Differentiated Thyroid Cancer. Thyroid, 24 (11), 1594–1599. doi: http://doi.org/10.1089/thy.2014.0173

24. Lee, J., Soh, E.-Y. (2010). Differentiated Thyroid Carcinoma Presenting With Distant Metastasis at Initial Diagnosis. Annals of Surgery, 251 (1), 114–119. doi: http://doi.org/10.1097/sla.0b013e3181b7faf6

25. Sugitani, I., Fujimoto, Y., Yamamoto, N. (2008). Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery, 143 (1), 35–42. doi: http://doi.org/10.1016/j.surg.2007.06.011

26. Wreesmann, V. B., Nixon, I. J., Rivera, M., Katabi, N., Palmer, F., Ganly, I. et. al. (2015). Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. Thyroid, 25 (5), 503–508. doi: http://doi.org/10.1089/thy.2015.0052

27. Hotomi, M., Sugitani, I., Toda, K., Kawabata, K., Fujimoto, Y. (2012). A Novel Definition of Extrathyroidal Invasion for Patients with Papillary Thyroid Carcinoma for Predicting Prognosis. World Journal of Surgery, 36 (6), 1231–1240. doi: http://doi.org/10.1007/s00268-012-1518-z

28. Yu, X.-M., Lo, C.-Y., Lam, A. K.-Y., Leung, P., Luk, J. M. (2008). Serum Vascular Endothelial Growth Factor C Correlates With Lymph Node Metastases and High-Risk Tumor Profiles in Papillary Thyroid Carcinoma. Annals of Surgery, 247 (3), 483–489. doi: http://doi.org/10.1097/sla.0b013e31815fa447

29. Tam, A. A., Özdemir, D., Çuhacı, N., Başer, H., Aydın, C., Yazgan, A. K. Et. al. (2016). Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine, 53 (3), 774–783. doi: http://doi.org/10.1007/s12020-016-0955-0

30. Lang, B. H.-H., Wong, K. P., Cheung, C. Y., Wan, K. Y., Lo, C.-Y. (2012). Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis. Annals of Surgical Oncology, 20 (4), 1329–1335. doi: http://doi.org/10.1245/s10434-012-2711-x

Рекомендовано до публікації: д-р мед. наук Болгов М. Ю. Received date 12.06.2019 Accepted date 26.06.2019 Published date 31.07.2019

Bogdan Huda, PhD, Senior Researcher, Department of Surgical, State Institution "V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine", Vyshgorodska str., 69, Kyiv, Ukraine, 04114 E-mail: bguda@ukr.net